Formulary Watch |

Azstarys is approved to treat patients 6 years and older.

Most of the suspected cases of myocarditis developed after the second dose of the vaccine and were among younger males.

The company’s stock began dropping on Tuesday with analyst expectation the FDA will issue a Complete Response Letter for tenapanor, its chronic kidney disease therapy.

Eight out of 10 covered U.S. commercial lives now have access to the H. pylori therapy.

This research sought to understand the relationship of prior medication exposure, existing health conditions, and COVID-19 outcomes using data from the American Heart Association’s COVID-19 Cardiovascular Disease Registry.

Current drug shortages based on FDA data, prepared by Formulary Watch.

FDA staff raised safety concerns ahead of the advisory panel hearing.

Merck has submitted the data from the study KEYNOTE-522 to the FDA for review.

Committee members raised safety concerns about FibroGen/AstraZeneca’s oral therapy roxadustat.

After generic entry, Zytiga’s market share fell to about 14% and monthly net sales across the entire market fell 85%.

New analysis suggests that even with rebates, the new Alzheimer’s therapy could have implications for Medicaid drug spending.

A permanent code is expected in the third quarter of 2021.

The therapy for opioid-induced constipation has no restrictions on an unidentified national formulary that serves these Blues plans.

The new indication provides a subcutaneous option for multiple myeloma that can be administrated in minutes, rather than hours.

Jardiance lowered risk of hospitalization from acute kidney injury but increased risk of hospitalized from diabetic ketoacidosis compared with a DPP4 inhibitor in one interim analysis.

Commercial insurers are beginning to provide coverage information on Biogen’s controversial therapy.

This is part of a larger effort by President Joe Biden to promote competition in the American economy.

This is the eighth generic version of the drug to treat insomnia.

Orally dissolving film formulation of riluzole is now available for patients who have difficulty swallowing.

New data show efficacy in all forms of heart failure regardless of ejection fraction.